• 1
    Brennan VM, Cochrane S, Fletcher C, Hendy D, Powell P. Surveillance of adverse reactions in patients self-infusing intravenous immunoglobulin at home. J Clin Immunol 1995; 15: 1169.
  • 2
    Chapel HM for the Consensus Panel. Consensus on diagnosis and management of primary antibody deficiencies. Br Med J 1994; 308: 5815.
  • 3
    Misbah SA, Chapel HM. Adverse effects of intravenous immunoglobulin. Drug Safety 1993; 9: 25462.
  • 4
    Chapel HM, Brennan VM, Delson E. Immunoglobulin replacement therapy by self-infusion at home. J Clin Immunol 1988; 73: 1602.
  • 5
    Bjorkander J, Hammarstrom L, Smith CIE, Buckley R, Cunningham-Rundles C, Hanson LA. Successful immunoglobulin prophylaxis in patients with antibody deficiency syndromes in the presence of anti-IgA. J Clin Immunol 1987; 7: 815.
  • 6
    Chapel HM, Spickett GP, Ericson D, Engl W, Eibl MM, Bjorkander J. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol 2000; 20: 94100.
  • 7
    Toogood JH. Risk of anaphylaxis in patients receiving beta-blocker drugs. J Allergy Clin Immunol 1988; 81: 15.
  • 8
    Goulet JP, Perusse R, Turcotte JY. Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions. Oral Surg Oral Med Oral Path 1992; 74: 6927.